Summary
Safety, tolerability, and preliminary efficacy data expected by early 2027
BOSTON–(BUSINESS WIRE)–#UKK0018–Ukko, Inc., a biotechnology company re-inventing immunotherapy for allergic diseases, today announced that the first participant has been successfully dosed in its Phase 1/2a clinical study…
Source: BioSpace
AI News Q&A (Free Content)
Q1: What is UKK-0018 and how is it being used in the treatment of peanut allergies?
A1: UKK-0018 is a computationally designed modified peanut protein encoded in an mRNA/Lipid-Nanoparticle (LNP) and expressed following intramuscular injection. It is intended to reduce patient risk by inducing protective B and T cell responses, such as the production of protective IgG antibodies from B cells and expansion of T cells, to inhibit allergic responses specifically. This is currently being assessed in a Phase 1/2a trial for its safety, tolerability, and preliminary efficacy in individuals with peanut allergies.
Q2: What are the goals of Ukko's Phase 1/2a clinical study for UKK-0018?
A2: The Phase 1/2a clinical study aims to evaluate the safety, tolerability, and preliminary efficacy of UKK-0018 in participants with peanut allergies. It plans to enroll 32 participants across clinical sites in Australia and New Zealand, with initial data expected by early 2027. The study will assess if participants can increase their tolerated dose of peanut protein without severe symptoms and if they can ingest a significant amount of peanut protein following treatment.
Q3: How does Peanut Oral Immunotherapy (P-OIT) compare with UKK-0018 in terms of safety and efficacy?
A3: Peanut Oral Immunotherapy (P-OIT) has been shown to be a feasible strategy for treating peanut allergies, allowing for increased consumption of peanut proteins with a significant reaction threshold. However, UKK-0018 represents a novel approach by using a modified protein through mRNA/LNP to induce specific immune responses, which could potentially offer a more targeted and safer treatment option, pending results from ongoing trials.
Q4: What recent findings have been made regarding sublingual immunotherapy for peanut allergies?
A4: A recent clinical study confirmed that peanut sublingual immunotherapy (SLIT) is both safe and effective for young children aged 1 to 4 years. Remission of the peanut allergy was possible after three months of stopping the treatment, indicating its potential as a long-term solution for managing peanut allergies.
Q5: What insights were gained from recent research on the role of cannabis exposure in peanut allergy development?
A5: Recent research highlighted a case where passive cannabis smoke exposure was linked to peanut allergy development in a child due to sensitization to Ara h 9, a component of peanuts. This suggests that environmental factors, such as exposure to cannabis, may play a role in the onset of peanut allergies, providing new insights into allergy prevention strategies.
Q6: What is the significance of the Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergies?
A6: The Phase 3 trial demonstrated the efficacy of epicutaneous immunotherapy in increasing the reaction threshold for peanut allergies in toddlers, suggesting a promising alternative to traditional oral immunotherapy. This method may offer a safer and less invasive option for young children unable or unwilling to undergo oral immunotherapy.
Q7: How does the use of omalizumab enhance the effectiveness of peanut allergy treatments?
A7: Omalizumab, an anti-IgE monoclonal antibody, has been shown to significantly increase the tolerated dose of peanut proteins when used alone or in combination with oral immunotherapy. It aids in successful desensitization for individuals with severe allergies, offering a potentially superior treatment strategy compared to placebo.
